|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:temple
gptkb:2018
gptkb:Achillion_Pharmaceuticals
gptkb:Syntimmune
|
|
gptkbp:ceo
|
gptkb:David_Hallal
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Asia
gptkb:United_States
Phase 1
Phase 2
Phase 3
ALX N1210
ALX N1830
ALX N2050
|
|
gptkbp:developed_by
|
gptkb:Eculizumab
gptkb:Ravulizumab
ALX N1210
ALX N1830
ALX N2050
C5 inhibitors
|
|
gptkbp:employees
|
approximately 3,000
|
|
gptkbp:founded
|
gptkb:1992
|
|
gptkbp:founder
|
gptkb:Leonard_Bell
|
|
gptkbp:headquarters
|
gptkb:Boston,_Massachusetts
gptkb:United_States
|
|
gptkbp:healthcare
|
gptkb:2017
gptkb:2018
gptkb:2019
gptkb:2020
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Alexion Pharmaceuticals, Inc.
|
|
gptkbp:market_cap
|
$30 billion (2020)
|
|
gptkbp:notable_products
|
gptkb:Soliris
gptkb:Ultomiris
|
|
gptkbp:partnership
|
gptkb:Sanofi
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Regeneron_Pharmaceuticals
gptkb:Amgen
|
|
gptkbp:research_areas
|
neurology
hematology
immunology
|
|
gptkbp:research_focus
|
autoimmune diseases
genetic diseases
complement inhibition
|
|
gptkbp:revenue
|
$1.5 billion (2020)
|
|
gptkbp:specializes_in
|
rare diseases
|
|
gptkbp:subsidiary
|
gptkb:Syntimmune
|
|
gptkbp:symbol
|
gptkb:ALXN
|
|
gptkbp:website
|
www.alexion.com
|
|
gptkbp:bfsParent
|
gptkb:Soliris
|
|
gptkbp:bfsLayer
|
5
|